Medical Information
In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
ATGAM® Adverse Reactions (lymphocyte immune globulin, anti-thymocyte globulin [equine])
6 ADVERSE REACTIONS
The most clinically significant adverse reactions are anaphylaxis, infection, thrombocytopenia, leukopenia, arthralgia, edema, bradycardia, and abnormal renal and liver function tests.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of ATGAM has been evaluated in 367 patients with renal transplant and 109 patients with aplastic anemia.
The renal transplantation and aplastic anemia patients received a similar dosing regimen, and these data were pooled to obtain the frequencies listed in Tables 1 and 2 below.
The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia.
| Adverse Reaction*,† | ATGAM |
|---|---|
| Frequency (%) | |
| (N = 476) | |
| Pyrexia | 39.5 |
| Chills | 26.5 |
| Rash | 25.6 |
| Thrombocytopenia | 21.6 |
| Leukopenia | 17.9 |
| Arthralgia | 17.2 |
| Urticaria | 9.2 |
| Headache | 5.3 |
| Pruritus | 4.6 |
| Nausea | 4.2 |
| Infection | 3.4 |
| Vomiting | 3.4 |
| Thrombophlebitis | 3.2 |
| Hypertension | 2.9 |
| Hypotension | 2.9 |
| Diarrhea | 2.9 |
| Abdominal pain upper | 2.7 |
| Chest pain | 2.7 |
| Infusion site pain | 2.1 |
| Edema | 2.1 |
| Bradycardia | 1.5 |
| Back pain | 1.5 |
| Lymphadenopathy | 1.3 |
| Arteriovenous fistula thrombosis | 1.3 |
| Dizziness | 1.1 |
| Dyspnea | 1.1 |
| Tachycardia | 1.1 |
| Liver function test abnormal | 1.0 |
| Adverse Reaction*,† | ATGAM |
|---|---|
| Frequency (%) | |
| (N = 476) | |
| Convulsion | 0.8 |
| Pleural effusion | 0.8 |
| Night sweats | 0.8 |
| Serum sickness | 0.6 |
| Hyperglycemia | 0.6 |
| Stomatitis | 0.6 |
| Renal function test abnormal | 0.6 |
| Herpes simplex | 0.4 |
| Agitation | 0.4 |
| Hiccups | 0.4 |
| Proteinuria | 0.4 |
| Asthenia | 0.4 |
| Malaise | 0.4 |
| Wound dehiscence | 0.4 |
| Anaphylactic reaction | 0.2 |
| Encephalitis | 0.2 |
| Paresthesia | 0.2 |
| Renal artery thrombosis | 0.2 |
| Iliac vein occlusion | 0.2 |
| Laryngospasm | 0.2 |
| Pulmonary edema | 0.2 |
| Dermatitis allergic | 0.2 |
| Periorbital edema | 0.2 |
| Toxic epidermal necrolysis | 0.2 |
6.2 Post-Marketing Experience
The following adverse reactions have been identified during post approval use of ATGAM. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Infections and infestations: Hepatitis viral, Localized infection, Systemic infection
Blood and lymphatic system disorders: Anemia, Eosinophilia, Granulocytopenia, Hemolysis, Hemolytic anemia, Neutropenia, Pancytopenia
Psychiatric disorders: Confusional state, Disorientation
Nervous system disorders: Dyskinesia, Syncope, Tremor
Cardiac disorders: Cardiac failure congestive
Vascular disorders: Deep vein thrombosis, Vasculitis
Respiratory, thoracic and mediastinal disorders: Apnea, Cough, Epistaxis, Oropharyngeal pain
Gastrointestinal disorders: Abdominal pain, Gastrointestinal hemorrhage, Gastrointestinal perforation, Oral pain
Skin and subcutaneous tissue disorders: Hyperhidrosis
Musculoskeletal and connective tissue disorders: Flank pain, Muscle rigidity, Myalgia, Pain in extremity
Renal and urinary disorders: Kidney enlargement, Kidney rupture, Renal failure acute
Congenital, familial and genetic disorders: Aplasia
General disorders and administration site conditions: Infusion site erythema, Infusion site swelling, Pain
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
ATGAM® Quick Finder
Resources
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
*9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch
